Skip to search formSkip to main contentSkip to account menu

LY 293111

Known as: LY-293111, LY293111, VML295 
National Institutes of Health

Related topics

Related topics

2 relations
Benzoate

Broader (1)

Benzoates

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Leukotriene receptor antagonists, LY293111 and ONO-1078, protect neurons from the sPLA2-IB-induced neuronal cell death independently of blocking their receptors
2006
2006
Randomized phase II trial of cisplatin/gemcitabine with or without LY293111, a multiple eicosonaid pathway modulator, in patients with chemotherapy naïve advanced non-small cell lung carcinoma.
7024 Background: The eicosanoid pathway is altered in NSCLC. Pharmacological activators of peroxisome proliferator-activated… 
2005
2005
Randomized double-blind phase II trial comparing gemcitabine (GEM) plus LY293111 vs. GEM plus placebo in advanced adenocarcinoma of the pancreas
4092 Background: LY293111 (LY) is a novel oral anticancer agent with known leukotriene B4 receptor antagonist and peroxisome… 
Review
2004
Review
2004
Molecular targeting therapy for pancreatic cancer
Pancreatic carcinogenesis is driven by multiple genetic and epigenetic changes. The epidermal growth factor receptor (EGFR) and… 
2004
2004
Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111
The arachidonic acid metabolic pathway is currently under active investigation as a promoter of malignancy and several molecules… 
2003
2003
Preclinical characterization of 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic acid metabolism: in vitro species comparison and in vivo disposition in…
Assessment of the pharmacokinetics of [14C]2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy… 
2003
2003
LY293111 improves gemcitabine efficacy in a new fluorescent orthotopic model of pancreatic cancer in athymic mice
2002
2002
Leukotriene B 4 Receptor Antagonist LY 293111 Inhibits Proliferation and Induces Apoptosis in Human Pancreatic Cancer Cells 1
Purpose: The effects of leukotriene (LT) B4 and its receptor antagonist LY293111 on proliferation and apoptosis of human… 
2000
2000
VML 295 (LY‐293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasis
Leukotriene B4 (LTB4) receptor antagonists have been the subject of several studies in the treatment of inflammatory diseases… 
1998
1998
Investigation on a novel and specific leukotriene B4 receptor antagonist in the treatment of stable plaque psoriasis
The aim of the present study was to investigate the efficacy and clinical tolerability of the specific leukotriene B4 receptor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)